|
| 37139650 | Point-of-care urine tenofovir testing: making a good thing better. | | 2023 |
| 35416092 | Disclosure of HIV-serodiscordant relationships and association with viral suppression: results from the Positive Plus One study. | AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV | 2023 |
| 35920743 | Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. | | 2023 |
| 37934531 | Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic. | | 2023 |
| 37779267 | Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV. | | 2023 |
| 37470926 | Assessment of Drug-Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations. | | 2023 |
| 36646278 | Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs. | | 2023 |
| 36536672 | Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286). | | 2022 |
| 35834528 | A randomized control trial of high-dose micronutrient-antioxidant supplementation in healthy persons with untreated HIV infection. | PLoS One | 2022 |
| 36288543 | Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study. | Journal of acquired immune deficiency syndromes (1999) | 2022 |
| 36159017 | Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue. | | 2022 |
| 35939812 | Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. | Annals of Internal Medicine | 2022 |
| 35543964 | Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study. | Advances in Therapy | 2022 |
| 34508360 | Life-long Antiretroviral Therapy: Playing the Long Game. | Clinical Infectious Diseases | 2021 |
| 35992258 | Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: AÂ CANUHCÂ analysis. | Canadian Liver Journal | 2021 |
| 35989890 | Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT). | Canadian Liver Journal | 2021 |
| 32166305 | Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. | Clinical Infectious Diseases | 2021 |
| 33749086 | Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. | J Viral Hepat | 2021 |
| 33677545 | Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. | Clinical Infectious Diseases | 2021 |
| 33306853 | Distinct Hepatitis B and HIV co-infected populations in Canada. | Journal of Viral Hepatitis | 2021 |
| 31300820 | Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International St | Clinical Infectious Diseases | 2020 |
| 35992533 | The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis C. | Canadian Liver Journal | 2020 |
| 35990509 | Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective study. | Canadian Liver Journal | 2020 |
| 31568620 | Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. | Liver International | 2020 |
| 32051160 | Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance. | BMJ Case Reports | 2020 |
| 32883249 | Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. | BMC Public Health | 2020 |
| 32639211 | Targeted Outreach, Education, and Point-of-Care Testing for HIV and Hepatitis C: Strategies to Address HIV Infection in Marginalized Communities in Vancouver. | AIDS Patient Care and STDs | 2020 |
| 32889855 | Treatment of primary HIV infection: new data for a new era. | AIDS | 2020 |
| 30735896 | Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. | International Journal of Drug Policy | 2019 |
| 31641059 | Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network. | CMAJ open | 2019 |
| 31714430 | Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. | Journal of acquired immune deficiency syndromes (1999) | 2019 |
| 30529905 | Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. | | 2019 |
| 31176594 | Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada. | International Journal of Drug Policy | 2019 |
| 29608613 | Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging. | PLoS ONE | 2018 |
| 35990714 | Diagnosis and treatment of hepatitis C virus infection: a tool for engagement with people who inject drugs in Vancouver's Downtown Eastside. | Canadian Liver Journal | 2018 |
| 30352330 | Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. | International Journal of Drug Policy | 2018 |
| 29869645 | Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C. | Drugs of Today | 2018 |
| 30384028 | Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. | International Journal of Drug Policy | 2018 |
| 29992173 | Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. | Open Forum Infectious Diseases | 2018 |
| 29310928 | Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. | Lancet Gastroenterology and Hepatology, The | 2018 |
| 28199495 | Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. | Clinical Infectious Diseases | 2017 |
| 28633998 | Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. | International Journal of Drug Policy | 2017 |
| 28893184 | The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol. | BMC Infectious Diseases | 2017 |
| 28624134 | Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. | International Journal of Drug Policy | 2017 |
| 28521211 | Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. | Journal of Clinical Virology | 2017 |
| 28610605 | Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. | BMC Infectious Diseases | 2017 |
| 28396854 | A Hepatitis C Educational Needs Assessment of Canadian Healthcare Providers. | Canadian Journal of Gastroenterology and Hepatology | 2017 |
| 29116684 | Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. | Journal of the International AIDS Society | 2017 |
| 29071045 | Repeated spontaneous clearance of hepatitis C virus infection in the setting of long-term non-progression of HIV infection. | Infectious Disease Reports | 2017 |
| 26078357 | Accounting for dropout reason in longitudinal studies with nonignorable dropout. | Stat Methods Med Res | 2017 |